Get started
MIRA Pharmaceuticals, Inc.MIRA Pharmaceuticals, Inc.MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals

MIRA fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
MIRA has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company